175 related articles for article (PubMed ID: 36634196)
61. [Conservative treatment of benign prostatic hyperplasia].
Romics I
Orv Hetil; 2008 Oct; 149(40):1875-80. PubMed ID: 18815106
[TBL] [Abstract][Full Text] [Related]
62. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
[TBL] [Abstract][Full Text] [Related]
63. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Tarter TH; Vaughan ED
Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
[TBL] [Abstract][Full Text] [Related]
64. Kidney transplant complications from undiagnosed benign prostatic hypertrophy.
Lubetzky M; Ajaimy M; Kamal L; de Boccardo G; Akalin E; Kayler L
Clin Transplant; 2015 Jun; 29(6):539-42. PubMed ID: 25832848
[TBL] [Abstract][Full Text] [Related]
65. Conservative Treatment for Benign Prostatic Hyperplasia in Patients With Bladder Stones.
Yoshida T; Kinoshita H; Nakamoto T; Yanishi M; Sugi M; Murota T; Matsuda T
Urology; 2015 Sep; 86(3):450-3. PubMed ID: 26235850
[TBL] [Abstract][Full Text] [Related]
66. Medical therapy for benign prostatic hyperplasia: a review.
Van Asseldonk B; Barkin J; Elterman DS
Can J Urol; 2015 Oct; 22 Suppl 1():7-17. PubMed ID: 26497339
[TBL] [Abstract][Full Text] [Related]
67. Benign prostatic hyperplasia - progress in pathophysiology and management.
Dobrek Ł; Thor PJ
Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
[TBL] [Abstract][Full Text] [Related]
68. Progression of lower urinary tract symptoms after discontinuation of 1 medication from 2-year combined alpha-blocker and 5-alpha-reductase inhibitor therapy for benign prostatic hyperplasia in men--a randomized multicenter study.
Lin VC; Liao CH; Kuo HC
Urology; 2014 Feb; 83(2):416-21. PubMed ID: 24332123
[TBL] [Abstract][Full Text] [Related]
69. Letter to the editor for the article "5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data".
Song Y; Xu T
World J Urol; 2023 Nov; 41(11):3379-3380. PubMed ID: 37698635
[No Abstract] [Full Text] [Related]
70. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.
Thakrar DB; Douglas IJ; Smeeth L; Bhaskaran K
Wellcome Open Res; 2023; 8():295. PubMed ID: 38774490
[No Abstract] [Full Text] [Related]
71. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications.
Seftel A; Rosen R; Kuritzky L
Int J Impot Res; 2007; 19(4):386-92. PubMed ID: 17377613
[TBL] [Abstract][Full Text] [Related]
72. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
O'Leary MP
Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
[TBL] [Abstract][Full Text] [Related]
73. 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery.
Boyle P; Roehrborn C; Harkaway R; Logie J; de la Rosette J; Emberton M
Eur Urol; 2004 May; 45(5):620-6; discussion 626-7. PubMed ID: 15082205
[TBL] [Abstract][Full Text] [Related]
74. Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men.
Chang J; Choi S; Kim K; Park SM
J Clin Med; 2019 May; 8(5):. PubMed ID: 31121994
[TBL] [Abstract][Full Text] [Related]
75. The association of α-blockers and 5-α reductase inhibitors in benign prostatic hyperplasia with fractures.
Lim SY; Laengvejkal P; Panikkath R; Nugent K
Am J Med Sci; 2014 Jun; 347(6):463-71. PubMed ID: 24270079
[TBL] [Abstract][Full Text] [Related]
76. Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta-Analysis of Observational Studies.
Dai X; Fang X; Ma Y; Xianyu J
Medicine (Baltimore); 2016 May; 95(18):e3493. PubMed ID: 27149447
[TBL] [Abstract][Full Text] [Related]
77. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
[TBL] [Abstract][Full Text] [Related]
78. Finasteride Use and Risk of Bladder Cancer in a Multiethnic Population.
Zhu D; Srivastava A; Agalliu I; Fram E; Kovac EZ; Aboumohamed A; Schoenberg MP; Sankin AI
J Urol; 2021 Jul; 206(1):15-21. PubMed ID: 33617325
[TBL] [Abstract][Full Text] [Related]
79. Benign prostatic hyperplasia and subsequent risk of bladder cancer.
Kang D; Chokkalingam AP; Gridley G; Nyren O; Johansson JE; Adami HO; Silverman D; Hsing AW
Br J Cancer; 2007 May; 96(9):1475-9. PubMed ID: 17473820
[TBL] [Abstract][Full Text] [Related]
80. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
De Nunzio C; Presicce F; Tubaro A
Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
